Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Blood Cancer: early-phase trial registry
11 of 13 indexed Blood Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 11 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Blood Cancer: 13 US clinical trials tracked, 11 recruiting.
Blood Cancer is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition blood-cancer
OPEN 11 | RECR 85% | LATE 0 | EARLY 7 | RANK #1315 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Myeloid Leukemia Refractory (85% recruiting · 13 trials)
Blood Cancer lists 11 open slots (85% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Blood Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Blood Cancer is recruiting above its size-band peers.
11 of 13 indexed trials (84.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Blood Cancer research.
Memorial Sloan Kettering Cancer Center accounts for 2 of 13 trials (15.4%). 12 distinct sponsors appear on at least one study for this condition label.
-
Most Blood Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 86 among the 13 trials that report a genuine target (sentinel values excluded). 9 of those (69.2%) plan for fewer than 100 participants.
-
Blood Cancer research is mostly interventional.
11 interventional and 2 observational studies make up this index (84.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Immune Profiling for Cancer Immunotherapy Response
Dartmouth-Hitchcock Medical Center
NCT06116032
The Leukemia and Lymphoma Society (LLS) National Research Registry
Blood Cancer United
NCT04806295
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics
NCT06119685
Pharmacogenomics for Better Treatment of Fungal Infections in Cancer
The University of Queensland
NCT06510699
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
University of Maryland, Baltimore
NCT06482515
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Massachusetts General Hospital
NCT05646576
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Cancer Institute (NCI)
NCT06904066
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Memorial Sloan Kettering Cancer Center
NCT07052916
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Dana-Farber Cancer Institute
NCT06469307
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Jacqueline Garcia, MD
NCT07148180
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT05873205
Understanding the Implementation of Cued Exercise Using Wearable Devices and a Custom Smartphone Application Following Bone Marrow Transplant.
Medical College of Wisconsin
NCT06645132
Allogeneic Transplantation From Related Haploidentical Donors
Stanford University
NCT00185692
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Blood Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Blood Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Blood Cancer page
13 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Blood Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Blood Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Blood Cancer condition card totals 13 registered trials; most-linked intervention Anti-Thymocyte Globulin; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.